Angela M Lam joined Arbutus Biopharma Inc. in July 2020 and currently serves as the Vice President of Biology. Prior to Arbutus, Angela was the Senior Director at Janssen Pharmaceuticals and the Director at Novira Therapeutics. The Novira team discovered and developed NVR 3-778, a first-in-class capsid assembly modulator that demonstrated antiviral efficacy in chronic hepatitis B patients. Prior to Novira, Angela was a Senior Scientist at Roche and at Pharmasset, where she contributed to the research on antivirals targeting the hepatitis B virus and hepatitis C virus, respectively. During her time at Pharmasset, Angela contributed to various antivirals discovery programs including PSI-7977 (subsequently acquired by Gilead Sciences and approved as Sofosbuvir for the treatment of chronic hepatitis C). Angela received her bachelor degree from the University of California, Berkeley, and her doctoral degree from the University of British Columbia in Vancouver, Canada.